

# PLASMID-MEDIATED QUINOLONE RESISTANCE AMONG EXTENDED-SPECTRUM BETA- LACTAMASE PRODUCING *ENTEROBACTERIACEAE* FROM BLOODSTREAM INFECTIONS

JUDIT DOMOKOS<sup>1</sup>, KATALIN KRISTÓF<sup>2</sup> and DÓRA SZABÓ<sup>1\*</sup>

<sup>1</sup>Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary

<sup>2</sup>Labor Medicine Institute, Semmelweis University, Budapest, Hungary

(Received: 12 May 2016; accepted: 24 June 2016)

The purpose of this study was to determine prevalence and molecular characterization of plasmid-mediated quinolone resistance (PMQR) genes [*qnrA*, *qnrB*, *qnrC*, *qnrD*, *qnrS*, *aac(6′)-Ib-cr*, *qepA*, and *oqxAB*] among extended-spectrum beta-lactamase (ESBL)-producing *Escherichia coli* and *Klebsiella* spp. isolates from bloodcultures in Hungary. A total of 103 isolates were tested for quinolone susceptibility by microdilution method and PMQR genes were detected by polymerase chain reaction. About 40 ESBL-producing *E. coli* (39%) and 50 ESBL-producing *Klebsiella* spp. strains (48%) were resistant to ciprofloxacin; 40 ESBL-producing *E. coli* (39%) and 47 ESBL-producing *Klebsiella* spp. strains (45%) were resistant to levofloxacin; and 88 strains including 40 ESBL-producing *E. coli* (39%) and 48 (47%) ESBL-producing *Klebsiella* spp. were resistant to moxifloxacin. Among the 103 ESBL-producing isolates, 77 (75%) isolates (30 *E. coli* and 47 *Klebsiella* spp.) harbored PMQR genes. The most commonly detected gene was *aac(6′)-Ib-cr* (65%). The occurrence of *qnrS* gene was 6%. Interestingly, *qnrA*, *qnrB*, *qnrC*, *qnrD*, and *qepA* were not found in any isolates. Among 77 PMQR-positive isolates, 27 (35.1%) and 1 (1.3%) carried two and three different PMQR genes, respectively. Only *Klebsiella* spp. harbored more than one PMQR genes. Observing prevalence of PMQR genes in the last 8 years, the increasing incidence of *aac(6′)-Ib-cr* and *oqxAB* can be seen. Our results highlight high frequency of PMQR genes among ESBL-producing *Klebsiella pneumoniae* and *E. coli* isolates with an increasing dynamics in Hungary.

**Keywords:** plasmid-mediated quinolone resistance, *qnr*, *aac(6′)-Ib-cr*, *oqxAB*

## Introduction

Fluoroquinolones (FQs) possess an excellent activity against gram-negative bacteria especially against *Enterobacteriaceae* and have been extensively used for

\*Corresponding author; E-mail: [szabo.dora@med.semmelweis-univ.hu](mailto:szabo.dora@med.semmelweis-univ.hu)

treatment of infections caused by these pathogens since their introduction in the 1980s [1]. The mode of action of FQs is the inhibition of type II DNA topoisomerases, namely, gyrase and topoisomerase IV [2]. DNA gyrase is the primary target for quinolones in gram-negative bacteria due to higher sensitivity of that enzyme to quinolone inhibition and formation of drug–enzyme–DNA complexes in comparison to the sensitivity of other topoisomerases. Resistance to FQs was explained by accumulation of mutations in the chromosomal genes, encoding DNA gyrase and topoisomerase IV bacterial enzymes, namely, *gyrA*, *gyrB*, *parC*, and *parE*. Further resistance mechanisms are the decreased intracellular drug accumulation by upregulation of native chromosomally encoded efflux pump AcrAB or decreased expression of outer membrane porins, e.g., OmpF in *Escherichia coli* [1, 3–5].

Plasmid-mediated quinolone resistance (PMQR) determinants – *qnr* determinants (*qnrA*, *qnr*, *BqnrS*, *qnrC*, and *qnrD*), aminoglycoside acetyltransferase (*6'*-Ib-cr variant, and specific efflux pumps, namely, *QepA* and *OqxAB* – were discovered as new ways of FQ resistance, mainly in *Enterobacteriaceae*. The acquisition of *qnr* genes leads to low-level FQ resistance, which is meant to be higher minimal inhibitory concentration (MIC) values than the wild-type but still below the internationally approved resistance breakpoints by European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute. In the status of low-level resistance, bacterial strains have 100 times increased mutation frequency (from  $10^8$  to  $10^6$ ) on chromosomal gene (e.g., *gyr*), which facilitates the selection to high-level FQ resistance [6–9]. *PMQR* genes are frequently associated with various beta-lactamase genes, including extended-spectrum beta-lactamases (ESBLs) and narrow spectrum-beta-lactamases, as these resistance determinants are located on same plasmids. Resistance plasmids are usually transferable by conjugation that facilitates their dissemination between different *Enterobacteriaceae* species [9, 10].

In this study, our aim was to determine the PMQR determinants among ESBL-producing *Enterobacteriaceae* strains from bloodcultures.

## Materials and Methods

### *Bacterial strains*

In this study, 103 ESBL-producing *Enterobacteriaceae* isolates from bloodstream infections (49 *E. coli* and 54 *Klebsiella* spp.) of patients treated at intensive care units of Semmelweis University between 2010 and 2014 were collected. Species identification was done by MALDI-TOF/MS (Bruker Daltonik GmbH, Bremen, Germany).

### *Antibiotic susceptibility*

MIC values of nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin were determined by broth microdilution methods using EUCAST criteria on all 103 isolates [6]. *E. coli* ATCC 25922 and *Klebsiella pneumoniae* ATCC 700603 were reference strains for antimicrobial susceptibility testing.

### *Phenotypic detection of ESBL production*

Double-disk synergy tests were performed by placing disks of ceftazidime, cefotaxime, and cefepime at a distance of 20 and 30 mm (center to center) from a disk containing amoxicillin plus clavulanic acid (20/10 µg). A “keyhole” phenomenon was regarded as positive for ESBL production.

### *Detection of PMQR genes by PCR*

Detection of genes encoding PMQR – *qnrA*, *qnrB*, *qnrC*, *qnrD*, *qnrS*, *aac(6′)-Ib-cr*, *qepA* and *oqxAB* – was performed on all isolates. A single colony of each test isolate was resuspended in 400-µl double distilled water and was boiled at 100 °C for 15 min. A supernatant was obtained after centrifugation at 13,000 rpm for 15 min and was used as bacterial DNA template in polymerase chain reaction (PCR) assays. The primers for detection of *qnrA*, *qnrB*, *qnrC*, *qnrD*, *qnrS*, *aac(6′)-Ib-cr*, *qepA*, and *oqxAB* genes are shown in Table I. PCRs were performed with RedTaq DNA polymerase (Sigma-Aldrich, St. Louis, MO, USA), according to manufacturer’s instructions with 2 µl of DNA template in a total reaction volume of 30 µl. DNA amplification programs consisted of an initial denaturation step (96 °C for 5 min) followed by 30 cycles of denaturation (96 °C for 30 s), annealing for 30 s (annealing temperature for each primer set is shown in Table I), and extension (72 °C for 1 min), and a final extension of 5 min at 72 °C. Ten microliters of reaction mixture containing PCR product was analyzed by gelelectrophoresis in 0.8% (wt/vol) agarose gel (Sigma-Aldrich) with 120 V for 30 min in electrophoresis system (Bio-Rad, Hercules, CA, USA).

## **Results**

### *Antibiotic susceptibility*

About 40 ESBL-producing *E. coli* (39%) and 50 ESBL-producing *Klebsiella* spp. strains (48%) were resistant to ciprofloxacin; 40 ESBL-producing *E. coli*

**Table I.** Primers used in this study

Gene	Primer sequence (5' to 3')	Size of PCR product (bp)	Annealing temperature (°C)	Reference
<i>qnrA-F</i>	ATTTCTCACGCCAGGATTTG	516	53	[11]
<i>qnrA-R</i>	GATCGGCAAAGGTTAGGTCA			
<i>qnrB-F</i>	ATGACGCCATTACTGTATAA	469	53	[12]
<i>qnrB-R</i>	GATCGCAATGTGTGAAGTTT			
<i>qnrS-F</i>	ACG ACA TTC GTC AAC TGC AA	417	53	[11]
<i>qnrS-R</i>	TAA ATT GGC ACC CTG TAG GC			
<i>qnrC-F</i>	GGGTTGTACATTTATTGAATC	447	50	[13]
<i>qnrC-R</i>	TCCACTTTACGAGGTTCT			
<i>qnrD-F</i>	CGAGATCAATTTACGGGAATA	582	50	[14]
<i>qnrD-R</i>	AACAAGCTGAAGCGCCTG			
<i>aac(6')Ib-cr-F</i>	TTGCGATGCTCTATGAGTGGCTA	482	54	[15]
<i>aac(6')Ib-cr-R</i>	CTCGAATGCCTGGCGTGTTT			
<i>oqxA-F</i>	CTCGGCGCGATGATGCT	392	57	[16]
<i>oqxA-R</i>	CCACTCTTCACGGGAGACGA			
<i>oqxB-F</i>	TTCTCCCCGGCGGAAGTAC	512	64	
<i>oqxB-R</i>	CTCGGCCATTTTGGCGCGTA			
<i>qepA-F</i>	GCA GGT CCA GCA GCG GGT AG	199	60	[17]
<i>qepA-R</i>	CTT CCT GCC CGA GTA TCG TG			

(39%) and 47 ESBL-producing *Klebsiella* spp. strains (45%) were resistant to levofloxacin; and 88 strains including 40 ESBL-producing *E. coli* (39%) and 48 (47%) ESBL-producing *Klebsiella* spp. were resistant to moxifloxacin. The distribution of MIC values of ESBL-producing *E. coli* and *Klebsiella* spp. is shown in Figures 1 and 2.


#### Detection of PMQR genes

Among 103 ESBL-producing isolates, 77 (75%) harbored PMQR genes, and 30 *E. coli* and 47 *Klebsiella* spp. were detected. The most commonly detected gene was *aac(6')-Ib-cr* (65%). The occurrence of *qnrS* gene was 6%. Interestingly, *qnrA*, *qnrB*, *qnrC*, *qnrD*, and *qepA* were not found in any isolates.


Among 49 ESBL-producing *E. coli* strains, 29 harbored *aac(6')-Ib-cr* gene and one carried *qnrS*. In 19 isolates, PMQR genes were not detected.

Among 53 *K. pneumoniae*, 38 harbored *aac(6')-Ib-cr* gene and five isolates carried *qnrS*. 26 *K. pneumoniae* isolates were positive for *oqxA* and 22 for *oqxB* genes.

Only six isolates – one *E. coli*, four *K. pneumoniae*, and one *K. oxytoca* isolates – harbored *qnrS*. The characteristics of these strains are summarized



**Figure 1.** The MIC values (mg/L) of ESBL-producing *E. coli* isolates



**Figure 2.** The MIC (mg/L) values of ESBL-producing *Klebsiella* spp.

in Table II. Interestingly, the strain harboring *qnrS* did not contain other PMQR genes.

Among 77 PMQR-positive isolates, 27 (35.1%) and 1 (1.3%) carried two and three different PMQR genes, respectively. Only *Klebsiella* spp. harbored more than one gene. The distribution and coexistence of PMQR genes among the 103 ESBL-producing isolates are shown in Tables III and IV: The distribution of

**Table II.** Characteristics of *qnrS* harboring strain

Strain	MIC (mg/L)			PMQR genes
	Ciprofloxacin	Levofloxacin	Moxifloxacin	
<i>E. coli</i> 58	>128	>128	>128	<i>qnrS</i>
<i>K. pneumoniae</i> 33	>128	>128	>128	<i>qnrS, oqxA, oqxB</i>
<i>K. pneumoniae</i> 47	128	32	128	<i>qnrS</i>
<i>K. pneumoniae</i> 115	128	8	8	<i>qnrS</i>
<i>K. pneumoniae</i> 125	128	64	64	<i>qnrS</i>
<i>K. oxytoca</i> 37	<0.25	<0.25	1	<i>qnrS</i>


**Table III.** Distribution of PMQR genes among 103 ESBL producers

Resistance genes	Number (%) of all ESBL producers	Number (%) of ESBL-producing <i>Klebsiella</i> spp.
<i>aac(6')-Ib-cr</i>	67 (65%)	38 (70%)
<i>qnrA</i>	0 (0%)	0 (0%)
<i>qnrB</i>	0 (0%)	0 (0%)
<i>qnrC</i>	0 (0%)	0 (0%)
<i>qnrD</i>	0 (0%)	0 (0%)
<i>qnrS</i>	6 (5.8%)	5 (9%)
<i>qepA</i>	0 (0%)	0 (0%)
<i>oxxA</i>	26 (25.2%)	26 (48%)
<i>oxxB</i>	22 (21.4%)	22 (40%)

**Table IV.** Coexisting PMQR resistance genes among 103 ESBL producers

Coexisting resistance genes	Number (%) of all ESBL producers	Number (%) of ESBL-producing <i>Klebsiella</i> spp.
<i>aac(6')-Ib-cr, oxA</i> and <i>oxxB</i>	13 (12.6%)	13 (24%)
<i>qnrS, oxA</i> and <i>oxxB</i>	1 (0.97%)	1 (1.8%)
<i>oxxA</i> and <i>oxxB</i>	7 (6.8%)	7 (13%)
<i>aac(6')-Ib</i> and <i>qnrS</i>	2 (1.9%)	2 (3.8%)
<i>aac(6')-Ib</i> and <i>oxxA</i>	3 (2.9%)	3 (5.7%)

ciprofloxacin MIC (mg/L) values of *Klebsiella* spp. harboring no or one or two PMQR genes parallel is shown in Figure 3. There is no correlation between ciprofloxacin MIC values and number of the harbored PMQR genes, as ciprofloxacin MIC values of these strains ranged between 0.25 and 128 mg/L.



**Figure 3.** The distribution of ciprofloxacin MIC (mg/L) values of *Klebsiella* spp. harboring no or one or two PMQR genes

## Conclusions

This study demonstrated that the most prevalent PMQR gene was *aac* (6′)-*Ib-cr* (68.8%) followed by *oqxA* (48%), *oqxB* (40%), and *qnrS* (6.4%). Comparing these data to earlier report from Hungary, Szabó et al. [18] showed nearly the same frequency in *qnr* resistance genes among ESBL-producing strains 3% in ESBL-producing *K. pneumoniae* and 1.4% in ESBL-producing *E. coli* isolates. By contrast, *qnrA* gene was not detected in this study, only *qnrS* was observed among bloodculture isolates. On the other hand, *qnrA* has same frequency among urinary tract isolates (unpublished data, personal communication with Dr. Kocsis) compared to earlier published Hungarian data [18]. Frequency of *qnr* genes in *K. pneumoniae* isolates varies in different countries: in China, 65.5% [19]; Malaysia, 48.9% [20] USA, 11.1% [21]; Singapore, 5.2% [22]; Italy, 5.02% [23]; and Brazil, 2.3% [24]. In this study, among *E. coli* and *Klebsiella* spp., no *qnrD* was detected. This is not surprising, as other studies found this resistance determinant mainly in Proteaceae tribe (*Proteus* spp., *Morganella* spp., and *Providencia* spp.) of *Enterobacteriaceae* [25, 26].

Interestingly, in this work, the prevalence of *aac*(6′)-*Ib-cr* increased dramatically from 26.6% to 68.8%, since the first detection in Hungary [18]. Different frequency of *aac*(6′)-*Ib-cr* among ESBL producers has been reported in several countries, namely, 70.1% in Iran [27] and 16.2% in Spain [28].

*OqxAB*, as a multidrug efflux pump, confers resistance to quinolone, such as ciprofloxacin, flumequine, norfloxacin, and nalidixic acid, and other antibiotics, such as chloramphenicol and trimethoprim [29]. This study

demonstrated that among ESBL-producing *K. pneumoniae*, a prevalence of 48% and 40% for *oqxA* and *oqxB* genes, respectively, can be seen. Different countries reported various prevalence data: 76.3% for *oqxA* and 74.6% for *oqxB* in Spain [30] and 100% for both genes in China [31]. As in other studies, *qepA* was not present in our ESBL-producing clinical isolates [27, 32].

In this study, there was no correlation between quinolone MIC values and harbored PMQR determinants, as four PMQR harboring strains exhibited susceptible ciprofloxacin MICs, while 45 PMQR-positive strains were resistant to FQs.

In summary, our results of this study reflected considerable frequency of *aac* (6′)-*Ib-cr* and efflux pump genes among ESBL-positive *K. pneumoniae* clinical isolates in Semmelweis University Clinics. This high frequency of PMQR genes indicated that early detection and routine screening of ESBL-producing *K. pneumoniae* and PMQR carriage seems necessary.

Earlier studies from Hungary demonstrated that diverse fitness cost associated with resistance to FQs allowed the extensive dissemination of major international clones of multiresistant *K. pneumoniae* in healthcare settings [33]. Other data showed that ciprofloxacin MIC values may play a role in dissemination of major *K. pneumoniae* clones [34]. A study demonstrated the need for reduced FQ consumption to prevent the spread of antimicrobial resistant microorganisms among healthcare settings [35].

In addition, it is important to note carbapenemase production of *Enterobacteriaceae*. A study described that among 883 ESBL-positive *Enterobacteriaceae*, 1.6% were carbapenem resistant. For the optimal detection of carbapenem-resistant microorganisms, molecular biological methods are recommended. However, in resource-limited settings, a combination of phenotypic tests can be applied in diagnostic labs [36].

The high prevalence of PMQR determinants should be considered as a wake-up call, because of the latent ability of these genetic platforms, they may recruit novel resistance mechanisms and promote the emergence of multidrug resistant isolates.

### Acknowledgements

We thank Natasa Pesti for her valuable technical help. This study was supported by the Hungarian National Scientific Research Fund under Grant No. OTKA 108481.



## References

1. Robicsek, A., Jacoby, G. A., Hooper, D. C.: The worldwide emergence of plasmid-mediated quinolone resistance. *Lancet Infect Dis* **6**, 629–640 (2006).
2. Levine, C., Hiasa, H., Mariani, K. J.: DNA gyrase and topoisomerase IV: Biochemical activities, physiological roles during chromosome replication, and drug sensitivities. *Biochim Biophys Acta* **1400**, 29–43 (1998).
3. Jacoby, G. A.: Mechanisms of resistance to quinolones. *Clin Infect Dis* **41**, 120–126 (2005).
4. Huang, W. M.: Bacterial diversity based on type II DNA topoisomerase genes. *Annu Rev Genet* **30**, 79–107 (1996).
5. Mazzariol, A., Zuliani, J., Cornaglia, G., Rossolini, G. M., Fontana, R.: AcrAB efflux system: Expression and contribution to fluoroquinolone resistance in *Klebsiella* spp. *Antimicrob Agents Chemother* **46**, 3984–3986 (2002).
6. EUCAST: <http://www.eucast.org>.
7. CLSI: <http://www.clsi.org>.
8. Martínez-Martínez, L., Pascual, A., Jacoby, G. A.: Quinolone resistance from a transferable plasmid. *Lancet* **14**, 797–799 (1998).
9. Rodríguez-Martínez, J. M., Cano, M. E., Velasco, C., Martínez-Martínez, L., Pascual, A.: Plasmid-mediated quinolone resistance: An update. *J Infect Chemother* **17**, 149–182 (2011).
10. Kocsis, B., Kocsis, E., Fontana, R., Cornaglia, G., Mazzariol, A.: Identification of *bla*<sub>LAP-2</sub> and *qnrS1* genes in the internationally successful *Klebsiella pneumoniae* ST147 clone. *J Med Microbiol* **62**, 269–273 (2013).
11. Robicsek, A., Strahilevitz, J., Sahm, D. F., Jacoby, G. A., Hooper, D. C.: *qnr* Prevalence in ceftazidime-resistant *Enterobacteriaceae* isolates from the United States. *Antimicrob Agents Chemother* **50**, 2872–2874 (2006).
12. Jacoby, G. A., Walsh, K. E., Mills, D. M., Walker, V. J., Oh, H., Robicsek, A., Hooper, D. C.: *qnrB*, another plasmid-mediated gene for quinolone resistance. *Antimicrob Agents Chemother* **50**, 1178–1182 (2006).
13. Wang, M., Guo, Q., Xu, X., Wang, X., Ye, X., Wu, S., Hooper, D. C.: New plasmid-mediated quinolone resistance gene, *qnrC*, found in a clinical isolate of *Proteus mirabilis*. *Antimicrob Agents Chemother* **53**, 1892–1897 (2009).
14. Cavaco, L. M., Hasman, H., Xia, S., Aarestrup, F. M.: *qnrD*, a novel gene conferring transferable quinolone resistance in *Salmonella enterica* serovars Kentucky and Bovismorbificans of human origin. *Antimicrob Agents Chemother* **53**, 603–608 (2009).
15. Park, C. H., Robicsek, A., Jacoby, G. A., Sahm, D., Hooper, D. C.: Prevalence in the United States of *aac(6)-Ib-cr* encoding a ciprofloxacin-modifying enzyme. *Antimicrob Agents Chemother* **50**, 3953–3955 (2006).
16. Kim, H. B., Wang, M., Park, C. H., Kim, E. C., Jacoby, G. A., Hooper, D. C.: *oqxAB* encoding a multidrug efflux pump in human clinical isolates of *Enterobacteriaceae*. *Antimicrob Agents Chemother* **53**, 3582–3584 (2009).
17. Yamane, K., Wachino, J., Suzuki, S., Arakawa, Y.: Plasmid-mediated *qepA* gene among *Escherichia coli* clinical isolates from Japan. *Antimicrob Agents Chemother* **52**, 1564–6 (2008).
18. Szabó, D., Kocsis, B., Rókus, L., Szentandrassy, J., Katona, K., Kristóf, K., Nagy, K.: First detection of plasmid-mediated, quinolone resistance determinants *qnrA*, *qnrB*, *qnrS* and

- aac(6′)-Ib-cr* in extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in Budapest, Hungary. J Antimicrob Chemother **62**, 630–632 (2008).
19. Yang, H., Chen, H., Yang, Q., Chen, M., Wang, H.: High prevalence of plasmid-mediated quinolone resistance genes *qnr* and *aac(6′)-Ib-cr* in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. Antimicrob Agents Chemother **52**, 4268–4273 (2008).
  20. Anuar, A. S. S., Yusof, M. Y. M., Tay, S. T.: Prevalence of plasmid-mediated *qnr* determinants and gyrase alteration in *Klebsiella pneumoniae* isolated from a university teaching hospital in Malaysia. Eur Rev Med Pharmacol Sci **17**, 1744–1747 (2013).
  21. Wang, M., Sahm, D. F., Jacoby, G. A., Hooper D. C.: Emerging plasmid-mediated quinolone resistance associated with the *qnr* gene in *Klebsiella pneumoniae* clinical isolates in the United States. Antimicrob Agents Chemother **48**, 1295–1299 (2004).
  22. Teo, J. W. P., Ng, K. Y., Lin, R. T. P.: Detection and genetic characterisation of *qnrB* in hospital isolates of *Klebsiella pneumoniae* in Singapore. Int J Antimicrob Agents **33**, 177–180 (2009).
  23. Kocsis, B., Mazzariol, A., Kocsis, E., Koncan, R., Fontana, R., Cornaglia, G.: Prevalence of plasmid-mediated quinolone resistance determinants in Enterobacteriaceae strains isolated in North-East Italy. J Chemother **25**, 36–40 (2013).
  24. Minarini, L. A. R., Poirel, L., Cattoir, V., Darini, A. L. C., Nordmann, P.: Plasmid-mediated quinolone resistance determinants among enterobacterial isolates from outpatients in Brazil. J Antimicrob Chemother **62**, 474–478 (2008).
  25. Mazzariol, A., Kocsis, B., Koncan, R., Kocsis, E., Lanzafame, P., Cornaglia, G.: Description and plasmid characterization of *qnrD* determinants in *Proteus mirabilis* and *Morganella morganii*. Clin Microbiol Infect **18**, 46–48 (2012).
  26. Guillard, T., Grillon, A., de Champs, C., Cartier, C., Madoux, J., Berçot, B., Lebreil, A. L., Lozniewski, A., Riahi, J., Vernet-Garnier, V., Cambau, E.: Mobile insertion cassette elements found in small non-transmissible plasmids in Proteaceae may explain *qnrD* mobilization. PLoS One **9**, 87801 (2014).
  27. Shams, E., Firoozeh, F., Moniri, R., Zibaei, M.: Prevalence of plasmid-mediated quinolone resistance genes among extended-spectrum  $\beta$ -Lactamase-producing *Klebsiella pneumoniae* human isolates in Iran. J Pathog **434391** (2015).
  28. Briales, A., Rodríguez-Martínez, J. M., Velasco, C., de Alba, P. D., Rodríguez-Baño, J., Martínez-Martínez, L., Pascual, A.: Prevalence of plasmid-mediated quinolone resistance determinants *qnr* and *aac(6′)-Ib-cr* in *Escherichia coli* and *Klebsiella pneumoniae* producing extended-spectrum  $\beta$ -lactamases in Spain. Int J Antimicrob Agents **39**, 431–434 (2012).
  29. Hansen, L. H., Jensen, L. B., Sorensen, H. I., Sorensen, S. J.: Substrate specificity of the OqxAB multidrug efflux pump in *Escherichia coli* and selected enteric bacteria. J Antimicrob Chemother **60**, 145–147 (2007).
  30. Rodríguez-Martínez, J. M., de Alba, P. D., Briales, A., Machuca, J., Lossa, M., Fernández-Cuenca, F., Rodríguez Baño, J., Martínez-Martínez, L., Pascual, Á.: Contribution of OqxAB efflux pumps to quinolone resistance in extended-spectrum- $\beta$ -lactamase-producing *Klebsiella pneumoniae*. J Antimicrob Chemother **68**, 68–73 (2013).
  31. Yuan, J., Xu, X., Guo, Q., Zhao, X., Ye, X., Guo, Y., Wang, M.: Prevalence of the *oqxAB* gene complex in *Klebsiella pneumoniae* and *Escherichia coli* clinical isolates. J Antimicrob Chemother **67**, 1655–1659 (2012).

32. Ferjani, S., Saidani, M., Amine, F. S., Boutiba-Ben Boubaker, I.: Prevalence and characterization of plasmid-mediated quinolone resistance genes in extended-spectrum  $\beta$ -lactamase-producing *Enterobacteriaceae* in a Tunisian hospital. *Microb Drug Resist* **21**, 158–66 (2015).
33. Füzi, M.: Has the use of fluoroquinolones facilitated the widespread dissemination of methicillin-resistant *Staphylococcus aureus* and extended-spectrum  $\beta$ -lactamase producing *Klebsiella pneumoniae* in the health care setting? *Acta Microbiol Immunol Hung* **61**, 399–405 (2014).
34. Melegh, S., Schneider, G., Horváth, M., Jakab, F., Emödy, L., Tigyi, Z.: Identification and characterization of CTX-M-15 producing *Klebsiella pneumoniae* clone ST101 in a Hungarian university teaching hospital. *Acta Microbiol Immunol Hung* **62**, 233–245 (2015).
35. Szabo, R., Böröcz, K.: Infections and antimicrobial use among institutionalized residents in Hungary: Increasing need of microbiological surveillance. *Acta Microbiol Immunol Hung* **62**, 29–44 (2015).
36. Somily, A. M., Garaween, G. A., Abukhalid, N., Absar, M. M., Senok, A. C.: Comparison of molecular and phenotypic methods for the detection and characterization of carbapenem resistant *Enterobacteriaceae*. *Acta Microbiol Immunol Hung* **63**, 69–81 (2016).